Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by TIAA Trust National Association

TIAA Trust National Association decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,561 shares of the biopharmaceutical company’s stock after selling 479 shares during the quarter. TIAA Trust National Association’s holdings in Gilead Sciences were worth $2,269,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC boosted its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.3 %

Shares of NASDAQ:GILD opened at $109.27 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company’s 50-day moving average price is $104.69 and its 200 day moving average price is $94.46. The company has a market cap of $136.08 billion, a PE ratio of 295.32, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Oppenheimer raised their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $104.52.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.